Autophagy in doxorubicin resistance: basic concepts, therapeutic perspectives and clinical translation
Yantao Zhang1, Yanqin Ji2,3, Yanyang Tu3,4,5
1Department of Clinical Medicine, The Fifth Clinical Institute, Zunyi Medical University, Zhuhai, Guangdong, China.
Abstract:
Doxorubicin (DOX) is still one of the leading compounds for cancer chemotherapy, but its clinical application has been restricted by the drug resistance. The emerging evidence has demonstrated that autophagy is a meticulously regulated by the lysosomal degradation as a regulator of this drug resistance. Autophagy can exert a pro-survival strategy under therapeutic stress through recycling cellular components, inhibiting apoptosis and remodelling metabolism, thereby enhancing carcinogenesis. The present review aims to highlight the interaction between autophagy and DOX resistance, providing the molecular machinery of autophagy and its control by genetic factors, microenvironmental factors and non-coding RNAs. Mechanistically, autophagy can be considered as protective or cytotoxic, relying on the cellular context, but in most cases, autophagy serves as a survival pathway promoting chemoresistance. The present review will also discuss about the function of DOX in autophagy induction through ROS generation, DNA damage response and AMPK/mTOR axis, whereas providing context-specific adaptations including mitophagy in cancer stem cells and lysosomal remodelling. The pre-clinical studies have highlighted the function of pharmacological compounds and nanoparticles for the regulation of autophagy for improving DOX sensitivity in cancer, accelerating therapeutic index. The strategies have focused on the application of small-molecule inhibitors, natural compounds, nanocarrier-mediated co-delivery of DOX with autophagy modulators and the development of combination therapeites providing the crosstalk of autophagy and cell death mechanisms in DOX resistance. The clinical translation depends on the development of more effective autophagy-targeted drugs in combination therapies. Hence, the present review highlights the role of autophagy as a biomarker and therapeutic factors in reversing DOX resistance. By elucidating the complex biology linking autophagy to drug resistance, it is emphasized that tailored approaches integrating autophagy modulation may yield more effective and less toxic cancer treatments.
Insights
Autophagy, a cellular recycling process, promotes resistance to doxorubicin (DOX) chemotherapy by helping cancer cells survive. Targeting autophagy could enhance DOX effectiveness and reduce cancer treatment toxicity.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- Doxorubicin (DOX) is a key chemotherapy agent, but its efficacy is limited by acquired drug resistance.
- Autophagy, a cellular degradation process, plays a dual role in cancer, often promoting survival and chemoresistance.
Purpose of the Study:
- To review the intricate relationship between autophagy and DOX resistance.
- To elucidate the molecular mechanisms underlying autophagy's role in DOX resistance.
- To explore therapeutic strategies targeting autophagy to overcome DOX resistance.
Main Methods:
- Literature review of pre-clinical and clinical studies.
- Analysis of molecular pathways involved in autophagy induction by DOX.
- Examination of genetic, microenvironmental, and non-coding RNA factors influencing autophagy.
Main Results:
- Autophagy generally acts as a pro-survival mechanism, enhancing chemoresistance by recycling cellular components and inhibiting apoptosis.
- DOX can induce autophagy via ROS generation, DNA damage response, and the AMPK/mTOR pathway.
- Context-specific adaptations like mitophagy and lysosomal remodeling contribute to DOX resistance.
Conclusions:
- Autophagy is a critical determinant of DOX resistance, acting as both a biomarker and a therapeutic target.
- Modulating autophagy through inhibitors, natural compounds, or combination therapies shows promise for improving DOX sensitivity.
- Clinical translation requires developing effective autophagy-targeted drugs for combination therapies to enhance cancer treatment outcomes.
Related Concept Videos
Treatment Resistant Cancers
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...


